Evidence map›Paper›PMID 42099773›Full record

ArticleBioactive materials2026

GSH-responsive nanovaccine triggers immunogenic cell death and potent memory T cell immunity for durable, recurrence-free tumor eradication.

Khang-Yen Pham, Thu Huyen Le Thi, Anil Giri, Jongjun Park, Jong-Sun Kang, Taeg Kyu Kwon, Jee-Heon Jeong, Simmyung Yook

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioactive materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Khang-Yen PhamSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Thu Huyen Le ThiDepartment of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Anil GiriDepartment of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Jongjun ParkDepartment of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Jong-Sun KangDepartment of Molecular Cell Biology, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Taeg Kyu KwonDepartment of Immunology, School of Medicine, Keimyung University, Daegu, 42601, Republic of Korea.
Jee-Heon JeongDepartment of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Simmyung YookSchool of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although nanovaccines hold promise for cancer immunotherapy, the engineering platforms that respond to tumor-specific cues and activate antitumor immunity remains challenging. Herein, a glutathione (GSH)-responsive immunogenic nanovaccine (SHINE) is developed, integrating immunogenic cell death (ICD)-inducing chemodynamic therapy (CDT) with immunotherapy to elicit synergistic

Indexed as

Chemodynamic therapyHollow manganese dioxideImmunogenic cell deathImmunotherapyLong-term memoryNanovaccines

Identifiers

PMID42099773
PMCPMC13145900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.